US 11,786,555 B2
RAR selective agonists in combination with immune modulators for cancer immunotherapy
Roshantha A. Chandraratna, San Juan Capistrano, CA (US); and Martin E. Sanders, Seattle, WA (US)
Assigned to Io Therapeutics, Inc., Spring, TX (US)
Filed by IO THERAPEUTICS, INC., Houston, TX (US)
Filed on Dec. 16, 2020, as Appl. No. 17/123,577.
Application 17/123,577 is a continuation of application No. 16/711,627, filed on Dec. 12, 2019, granted, now 10,874,694.
Application 16/711,627 is a continuation of application No. 16/519,544, filed on Jul. 23, 2019, granted, now 10,532,074, issued on Jan. 14, 2020.
Application 16/519,544 is a continuation of application No. 16/452,800, filed on Jun. 26, 2019, granted, now 10,532,073, issued on Jan. 14, 2020.
Application 16/452,800 is a continuation of application No. 16/117,372, filed on Aug. 30, 2018, granted, now 10,363,272, issued on Jul. 30, 2019.
Application 16/519,544 is a continuation of application No. 16/117,372, filed on Aug. 30, 2018, granted, now 10,363,272, issued on Jul. 30, 2019.
Claims priority of provisional application 62/552,814, filed on Aug. 31, 2017.
Prior Publication US 2021/0100844 A1, Apr. 8, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61P 35/02 (2006.01); A61K 31/4965 (2006.01); A61K 31/167 (2006.01); A61K 35/15 (2015.01); A61K 31/69 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 31/167 (2013.01); A61K 31/4965 (2013.01); A61K 35/15 (2013.01); A61P 35/02 (2018.01); A61K 31/69 (2013.01); A61K 2300/00 (2013.01)] 17 Claims
 
1. A method of potentiating chimeric antigen receptor-modified immune cells (CAR-MIC) cancer immunotherapy comprising administering at least one differentiating retinoic acid receptor (RAR) active agent, wherein the differentiating RAR active agent is a RARα agonist, to a cancer patient who is receiving, has received, or is scheduled to receive, CAR-MIC, wherein the RARα agonist is a CYP26 metabolism-resistant, RARα selective agonist having a structure of general formula (I)

OG Complex Work Unit Chemistry
wherein R1 is H or C1-6 alky, R2 and R3 are independently H or F, and R4 is a halogen;
wherein the RARα agonist is administered daily.